Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease
Deepak, Parakkal , Stobaugh, Derrick J., Deepak, Parakkal

Alimentary Pharmacology & Therapeutics | August 28, 2014 | Volume: 40 | Issue: 9 | Pages: 1035-1043

10.1111/apt.12936 | PMID 25164260 Get It

Elevated soluble IL‐2Rα, IL‐8, and MIP‐1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma
Sonbol, Mohamad Bassam , Stenson, Mary, Allmer, Cristine, LaPlant, Betsy, Weiner, George J. , Macon, William R. , Sonbol, Mohamad B., Maurer, Matthew J. , Cerhan, James R. , Witzig, Thomas E. , Gupta, Mamta , Sonbol, Mohamad B , Weiner, George

American Journal of Hematology | August 28, 2014 | Volume: 89 | Issue: 12 | Pages: No page available

10.1002/ajh.23838 | PMID 25164110 Get It

Mantle cell lymphoma (MCL) is a unique type of lymphoma with a prognosis intermediate between indolent and aggressive types. The purpose of this study was to study blood cytokine levels in newly diagnosed and relapsed MCL patients with respect to patterns of abnormalities and relationship to the MCL International Prognostic Index (MIPI) score. We analyzed blood levels of 30 cytokines using a multiplex ELISA in 88 patients with newly diagnosed MCL (pre‐treatment levels) and 20 with relapsed MCL and compared them with controls without known lymphoma. Elevated cytokine levels were compared with clinical outcome and the MIPI score. In the 88 newly diagnosed MCL patients, we found significantly elevated levels compared with controls of IL‐12, IP‐10, sIL‐2Rα, MIG, IL‐1RA, IL‐8, MIP‐1α, and MIP‐1β (all P < 0.05). Of these elevated cytokines, sIL‐2Rα, IL‐8, MIG, MIP‐1α, and MIP‐1β were predictive of inferior event‐free survival, and sIL‐2Rα (HR = 1.94; P = 0.038), IL‐8 (HR = 2.17; P = 0.015), and MIP‐1β (HR = 2.10; P = 0.016) were independent of MIPI score; only sIL‐2Rα (HR = 2.35; P = 0.041) was associated with overall survival after adjustment for MIPI. In the relapsed MCL patient group, the only significantly elevated plasma cytokines that predicted EFS were sIL‐2Rα (HR = 2.90; P = 0.04) and IL‐8 (HR = 3.75; P = 0.02). Elevated blood levels of sIL‐2Rα and the pro‐inflammatory cytokines IL‐8 and MIP‐1β are poor prognostic factors in MCL patients and independent of MIPI score. These factors, if validated, will provide important additions to the MIPI and guide the development of new therapies for patients with elevated levels of these cytokines. Am. J. Hematol. 89:E223–E227, 2014. © 2014 Wiley Periodicals, Inc.
Sensitivity and specificity of diagnostic ultrasound in the diagnosis of phrenic neuropathy
Boon, Andrea J. , Sekiguchi, Hiroshi , Harper, Caitlin J., Strommen, Jeffrey A., Ghahfarokhi, Leili Shahgholi, Watson, James C. , Sorenson, Eric J. , Ghahfarokhi, Leili S

Neurology | August 28, 2014 | Volume: 83 | Issue: 14 | Pages: 1264-1270

10.1212/wnl.0000000000000841 | PMID 25165390 Get It

Adherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Zsolt, Varon, Sepideh F., Gillard, Patrick, Hansen, Ryan N. , Devine, Emily Beth , Dodick, David W.

Cephalalgia | August 28, 2014 | Volume: 35 | Issue: 6 | Pages: 478-488

10.1177/0333102414547138 | PMID 25164920 Get It

Background Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life. Migraine-prevention guidelines recommend preventive medications as the standard of care for patients with frequent migraine. The aim of this study was to assess adherence to 14 commonly prescribed oral migraine-preventive medications (OMPMs) among patients with CM. Methods Retrospective claims analysis of a US claim database (Truven MarketScan® Databases) was queried to identify patients who were at least 18 years old, diagnosed with CM, and initiated an OMPM (antidepressants, beta blockers, or anticonvulsants) between January 1, 2008 and September 30, 2012. Medication possession ratios (MPR) and proportion of days covered (PDC) were calculated for each patient. A cutoff of ≥80% was used to classify adherence. The odds of adherence between OMPMs were compared using logistic regression models. Results Of the 75,870 patients identified with CM, 8688 met the inclusion/exclusion criteria. Adherence ranged between 26% to 29% at six months and 17% to 20% at 12 months depending on the calculation used to classify adherence (PDC and MPR, respectively). Adherence among the 14 OMPMs was similar except for amitriptyline, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate. Conclusion Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months.
Buprenorphine for Cancer Pain
Prommer, Eric

American Journal of Hospice and Palliative Medicine® | August 28, 2014 | Volume: 32 | Issue: 8 | Pages: 881-889

10.1177/1049909114547227 | PMID 25163678 Get It

Buprenorphine (BUP) is a semisynthetic derivative of the opium alkaloid thebaine found in the poppy Papaver somniferum. Its chemical structure contains the morphine structure but differs by having a cyclopropylmethyl group. Buprenorphine is a potent µ opioid agonist. Buprenorphine undergoes extensive first-pass metabolism in the liver and gut. The development of a transdermal BUP formulation in 2001 led to its evaluation in cancer pain. This article provides the practitioner with an update on the current role of BUP in cancer care. It highlights data suggesting effectiveness in various types of cancer pain. The article reviews pharmacology, routes of administration, adverse effects, drug interactions, and cost considerations.
Postcolonoscopy Followup Recommendations: Comparison with and without Use of Polyp Pathology
Ratuapli, Shiva K., Gurudu, Suryakanth, Atia, Mary A., Umar, Sarah B. , Harrison, M. Edwyn , Leighton, Jonathan A. , Ramirez, Francisco C. , Linder, Jeffrey A. , Gurudu, Suryakanth R, Crowell, Michael D.

Diagnostic and Therapeutic Endoscopy | August 27, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-7

10.1155/2014/683491 | PMID 25242879 Get It

Background. Appropriate recommendations for a followup exam after an index colonoscopy are an important quality indicator. Lack of knowledge of polyp pathology at the time of colonoscopy may be one reason that followup recommendations are not made. Aim. To describe and compare the accuracy of followup recommendations made at colonoscopy based on the size and number of polyps with recommendations made at a later date based on actual polyp pathology. Methods. All patients who underwent screening and surveillance colonoscopy from March, 2012, to August, 2012, were included. Surveillance recommendations from the endoscopy reports were graded as “accurate” or “not accurate” based on the postpolypectomy surveillance guidelines established by US Multisociety Task Force on Colon Cancer. Polyp pathology was then used to regrade the surveillance recommendations. Results. Followup recommendations were accurate in 759/884 (86%) of the study colonoscopies, based upon size and number of polyps with the assumption that all polyps were adenomatous. After incorporating actual polyp pathology, 717/884 (81%) colonoscopies had accurate recommendations. Conclusion. In our practice, the knowledge of actual polyp pathology does not change the surveillance recommendations made at the time of colonoscopy in the majority of patients.
Health Services Research and Managerial Epidemiology
Rohrer, James E.

Health Services Research and Managerial Epidemiology | August 27, 2014 | Volume: 1 | Issue: No issue available | Pages: No page available

10.1177/2333392814535521 | PMID 28462243 Get It

Comparing Stage at Diagnosis Among Patients With Breast Cancer Served by Military and Civilian Medical Care Systems
Salai, Silvija, Peoples, George E. , Stoodt, G, Danawi, Hadi, Rohrer, James E.

Health Services Research and Managerial Epidemiology | August 27, 2014 | Volume: 1 | Issue: No issue available | Pages: No page available

10.1177/2333392814533660 | PMID 28462242 Get It

Background: Breast cancer (BC) remains one of the top causes of cancer-related deaths in women in the United States, and little is known about the differences in access to health care between military and civilians. This study compared the differences in access to health care between military and civilian female patients with BC. In particular, this study examined whether patients with BC, in an equal access health care system such as the military, are diagnosed at an earlier stage of disease process in comparison to the patients with BC in the civilian health care system. Methods: Independent variables included military versus civilian care and demographic variables. Dependent variable was the stage of cancer at diagnosis. This cross-sectional study of 2 groups included data from 2198 women with BC (439 military and 1759 civilian) for years 2004 through 2008. Multiple logistic regression was used to analyze the data. Results: There was no difference in the early BC stage (0, I, and II) diagnosis prevalence rate between the military and the civilian groups (95% confidence interval [CI], P = .15). The logistic regression analysis indicated that both the health systems had equal performance with respect to the stage at diagnosis indicator but found that black patients had higher odds of being in the late stage (III and IV) BC group at diagnosis (1.62 OR, 1.14-2.30 CI, P = .0068) than white patients. Conclusions: Although no difference was found between the performance of the 2 health systems in the early (0, I, and II) versus late stage (III and IV) at diagnosis indicator, this study further confirms the existence of racial disparities in late-stage BC regardless of whether the patient was diagnosed in the civilian or military health system. More research is needed to further investigate the potential explanations of racial disparities other than just differences in access to health care.
A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease
Casteleijn, Niek F. , Visser, Folkert W., Drenth, Joost P.H. , Groen, Gerbrand J. , Hogan, Marie C., Gansevoort, Ron T., Drenth, J.P.H., Fijter, J.W. de, Gansevoort, R.T., Peters, D.J.M., Wetzels, J., Zietse, R., Hogan, Marie C. , Gevers, Tom J.G. , Hogan, Marie C., Gansevoort, Ron T., Drenth, J.P.H., Fijter, J.W. de, Gansevoort, R.T., Peters, D.J.M., Wetzels, J., Zietse, R., Hogan, Marie C , Drenth, Joost P H

Nephrology Dialysis Transplantation | August 27, 2014 | Volume: 29 | Issue: suppl_4 | Pages: iv142-iv153

10.1093/ndt/gfu073 | PMID 25165181 Get It

The Essential Roles of Chemistry in High-Throughput Screening Triage
Dahlin, Jayme L. , Walters, Michael A. , Walters, Michael A

Future Medicinal Chemistry | August 27, 2014 | Volume: 6 | Issue: 11 | Pages: 1265-1290

10.4155/fmc.14.60 | PMID 25163000 Get It